1. Hirai K, Arimitsu H, Umada K, Yokota K, Shen L, Ayada K, Kodama Y, Tsuji T, Hirai Y, and Oguma K. Passive oral immunization by egg yolk immunoglobulin (IgY) to Vibrio cholerae effectively prevents cholera. Acta Med Okayama. 64(3): 163-70, 2010
2. Kawabata T, Mitsui H, Yokota K, Ishio K, Oguma K, and Sano S. Induction of antibacterial activity in larvae of the blowfly Lucilia sericata by an infected environment. Medical and Veterinary Entomology. 24: 375-381, 2010.
3. T. Suzuki and S. Miyazaki, In silico analysis for the study of botulinum toxin structure, Quantum Bio-Informatics 26: 481-488, 2010
4. T. Urushibara, S. Akasaka, M. Ito, T. Suzuki and S. Miyazaki, 4. On the statics for micro-array data analysis, Quantum Bio-Informatics 26: 381-392, 2010
5. K. Niwa, T. Yoneyama, H. Ito, M. Taira, T. Chikai, H. Kouguchi, T. Suzuki, K. Hasegawa, K. Miyata, K. Inui, T. Ikeda, T. Watanabe and T. Ohyama, Sialic acid-dependent binding and transcytosis of serotype D botulinum neurotoxin and toxin complex in rat intestinal epithelial cells, Vet. Microbiol. 141: 312-320, 2010
6. H. Ito, Y. Sagane, K. Miyata, K. Inui, T. Matsuo, R. Horiuchi, T. Ikeda, T. Suzuki, K. Hasegawa, H. Kouguchi, K. Oguma, K. Niwa, T. Ohyama and T. Watanabe, HA-33 facilitates transport of the serotype D botulinum toxin across a rat intestinal epithelial cell monolayer, FEMS Immunol. Med. Microbiol. 61: 323-331, 2011
7. Shen L, Matsunami Y, Quan N, Kobayashi K, Matsuura E and Oguma K. In Vivo Oxidation，Platelet Activation and Simultaneous Occurrence of Natural Immunity in Atherosclerosis-Prone Mice. The Israel Medical Association Journal (IMAJ).Vol.13, MAY 2011
8. Viriyawattana N, Chongthaleong A, Oguma K,Yamamoto Y, Poonsuk K, Chalermchaikit T. The Prevalence and Phylogenetic Analysis of Clostridium botulinum in Soil at Nan Province of Thailand. Asian Biomedicine (Research Reviews and News). February 4th , 2011
9. Nakamura T, Tonozuka T, Ito S, Takeda Y, Sato R, Matsuo I, Ito Y, Oguma K and Nishikawa A. Molecular diversity of the two sugar-binding sites of the βtrefoil lectin HA33/C (HA1) from Clostridium botulinum type C neurotoxin. Arch Biochem Biophys. 512 (1): 69-77, 2011
10. Matsuo T, Miyata K, Inui K, Ito H, Horiuchi R, Ikeda T, Suzuki T, Yoneyama T, Oguma K, Niwa K, Watanabe T and Ohyama T, Characterization of sugar recognition by the toxin complex produced by the Clostridium botulinum serotype C variant strain Yoichi. FEMS Immunol Med Microbiol. 63: 35-43, 2011
11.Neri P, Tokoro S, Kobayashi R, Sugiyama T, Umeda K, Shimizu T, Tsuji T, Kodama Y, Oguma K and Mori H, Specific Egg Yolk Immunoglobulin as a New Preventive Approach for Shiga-Toxin-Mediated Diseases. PloS ONE 6(10), October 19, 2011
12.T. Yokoyama, M. B. Chancellor, K. Oguma, Y. Yamamoto, T. Suzuki, H. Kumon and A. Nagai, Botulinum toxin type A for the treatment of lower urinary tract disorders, Int. J. Urol. 19, 202-215, 2012
13. S. Ma, Study for the structures of the HA complexes produced by Clostridium botulinum type A mutant strain, OKAYAMA-IGAKKAISHI, 124: 137-143, 2012
14. K. Zhang, Y. Yamamoto, T. Suzuki, K. Yokota, S. Ma, Ni Nengah Dwi Fatmawati and K. Oguma, Clostridium botulinum Type E Toxins Bind to Caco-2 Cells by a Different Mechanism from That of Type A Toxins, Acta Medica Okayama, 66: 253-261, 2012
15. Y. Matsuka, T. Yokoyama, Y. Yamamoto, T. Suzuki, A. Nishikawa, T. Ohyama, T. Watanabe, T. Kuboki, A. Nagai and K. Oguma, Application of purified botulinum type A neurotoxin to experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasia, J. Toxicol, 2012:648384, 2012
16. Sagane Y, Miyashita S, Miyata K, Matsumoto T, Inui K, Hayashi S, Suzuki T, Hasegawa K, Yajima S, Yamano A, Niwa K, Watanabe T. Small-angle X-ray scattering reveals structural dynamics of the botulinum neurotoxin associating protein, nontoxic nonhemagglutinin, Biochem Biophys Res Commun, 425: 256-60, 2012
17. Yokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A, Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin, Acta Med Okayama. 66: 291-297, 2012
18. Ponnapakkam T, Katikaneni R, Suda H, Miyata S, Matsushita O, Sakon J, Gensure RC, A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice, Calcif Tissue Int. 91: 196-203, 2012
19. Philominathan ST, Koide T, Matsushita O, Sakon J, Bacterial collagen-binding domain targets undertwisted regions of collagen, Protein Sci, 21: 1554-1565, 2012
20. Bauer R, Wilson JJ, Philominathan ST, Davis D, Matsushita O, Sakon J, Structural comparison of ColH and ColG collagen-binding domains from Clostridium histolyticum, J Bacteriol, 195: 318-327, 2013
21. Ni Nengah Dwi Fatmawati, Sakaguchi Y, Suzuki T, Oda M, Shimizu K, Yamamoto Y, Sakurai J, Matsushita O, Oguma K, Phospholipase C Produced by Clostridium botulinum Types C and D:Comparison of Gene, Enzymatic, and Biological Activities with Those of Clostridium perfringens Alpha-toxin. Acta Med Okayama. 67: 9-18, 2013
2. Kawabata T, Mitsui H, Yokota K, Ishio K, Oguma K, and Sano S. Induction of antibacterial activity in larvae of the blowfly Lucilia sericata by an infected environment. Medical and Veterinary Entomology. 24: 375-381, 2010.
3. T. Suzuki and S. Miyazaki, In silico analysis for the study of botulinum toxin structure, Quantum Bio-Informatics 26: 481-488, 2010
4. T. Urushibara, S. Akasaka, M. Ito, T. Suzuki and S. Miyazaki, 4. On the statics for micro-array data analysis, Quantum Bio-Informatics 26: 381-392, 2010
5. K. Niwa, T. Yoneyama, H. Ito, M. Taira, T. Chikai, H. Kouguchi, T. Suzuki, K. Hasegawa, K. Miyata, K. Inui, T. Ikeda, T. Watanabe and T. Ohyama, Sialic acid-dependent binding and transcytosis of serotype D botulinum neurotoxin and toxin complex in rat intestinal epithelial cells, Vet. Microbiol. 141: 312-320, 2010
6. H. Ito, Y. Sagane, K. Miyata, K. Inui, T. Matsuo, R. Horiuchi, T. Ikeda, T. Suzuki, K. Hasegawa, H. Kouguchi, K. Oguma, K. Niwa, T. Ohyama and T. Watanabe, HA-33 facilitates transport of the serotype D botulinum toxin across a rat intestinal epithelial cell monolayer, FEMS Immunol. Med. Microbiol. 61: 323-331, 2011
7. Shen L, Matsunami Y, Quan N, Kobayashi K, Matsuura E and Oguma K. In Vivo Oxidation，Platelet Activation and Simultaneous Occurrence of Natural Immunity in Atherosclerosis-Prone Mice. The Israel Medical Association Journal (IMAJ).Vol.13, MAY 2011
8. Viriyawattana N, Chongthaleong A, Oguma K,Yamamoto Y, Poonsuk K, Chalermchaikit T. The Prevalence and Phylogenetic Analysis of Clostridium botulinum in Soil at Nan Province of Thailand. Asian Biomedicine (Research Reviews and News). February 4th , 2011
9. Nakamura T, Tonozuka T, Ito S, Takeda Y, Sato R, Matsuo I, Ito Y, Oguma K and Nishikawa A. Molecular diversity of the two sugar-binding sites of the βtrefoil lectin HA33/C (HA1) from Clostridium botulinum type C neurotoxin. Arch Biochem Biophys. 512 (1): 69-77, 2011
10. Matsuo T, Miyata K, Inui K, Ito H, Horiuchi R, Ikeda T, Suzuki T, Yoneyama T, Oguma K, Niwa K, Watanabe T and Ohyama T, Characterization of sugar recognition by the toxin complex produced by the Clostridium botulinum serotype C variant strain Yoichi. FEMS Immunol Med Microbiol. 63: 35-43, 2011
11.Neri P, Tokoro S, Kobayashi R, Sugiyama T, Umeda K, Shimizu T, Tsuji T, Kodama Y, Oguma K and Mori H, Specific Egg Yolk Immunoglobulin as a New Preventive Approach for Shiga-Toxin-Mediated Diseases. PloS ONE 6(10), October 19, 2011
12.T. Yokoyama, M. B. Chancellor, K. Oguma, Y. Yamamoto, T. Suzuki, H. Kumon and A. Nagai, Botulinum toxin type A for the treatment of lower urinary tract disorders, Int. J. Urol. 19, 202-215, 2012
13. S. Ma, Study for the structures of the HA complexes produced by Clostridium botulinum type A mutant strain, OKAYAMA-IGAKKAISHI, 124: 137-143, 2012
14. K. Zhang, Y. Yamamoto, T. Suzuki, K. Yokota, S. Ma, Ni Nengah Dwi Fatmawati and K. Oguma, Clostridium botulinum Type E Toxins Bind to Caco-2 Cells by a Different Mechanism from That of Type A Toxins, Acta Medica Okayama, 66: 253-261, 2012
15. Y. Matsuka, T. Yokoyama, Y. Yamamoto, T. Suzuki, A. Nishikawa, T. Ohyama, T. Watanabe, T. Kuboki, A. Nagai and K. Oguma, Application of purified botulinum type A neurotoxin to experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasia, J. Toxicol, 2012:648384, 2012
16. Sagane Y, Miyashita S, Miyata K, Matsumoto T, Inui K, Hayashi S, Suzuki T, Hasegawa K, Yajima S, Yamano A, Niwa K, Watanabe T. Small-angle X-ray scattering reveals structural dynamics of the botulinum neurotoxin associating protein, nontoxic nonhemagglutinin, Biochem Biophys Res Commun, 425: 256-60, 2012
17. Yokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A, Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin, Acta Med Okayama. 66: 291-297, 2012
18. Ponnapakkam T, Katikaneni R, Suda H, Miyata S, Matsushita O, Sakon J, Gensure RC, A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice, Calcif Tissue Int. 91: 196-203, 2012
19. Philominathan ST, Koide T, Matsushita O, Sakon J, Bacterial collagen-binding domain targets undertwisted regions of collagen, Protein Sci, 21: 1554-1565, 2012
20. Bauer R, Wilson JJ, Philominathan ST, Davis D, Matsushita O, Sakon J, Structural comparison of ColH and ColG collagen-binding domains from Clostridium histolyticum, J Bacteriol, 195: 318-327, 2013
21. Ni Nengah Dwi Fatmawati, Sakaguchi Y, Suzuki T, Oda M, Shimizu K, Yamamoto Y, Sakurai J, Matsushita O, Oguma K, Phospholipase C Produced by Clostridium botulinum Types C and D:Comparison of Gene, Enzymatic, and Biological Activities with Those of Clostridium perfringens Alpha-toxin. Acta Med Okayama. 67: 9-18, 2013
2010年以降 原著論文（計21報）